Cancer vaccine - CEL-SCI/Max Delbruck Center

Drug Profile

Cancer vaccine - CEL-SCI/Max Delbruck Center

Alternative Names: Breast cancer vaccine - CEL-SCI/Max Delbruck Center; Colon cancer vaccine - CEL-SCI/Max Delbruck Center

Latest Information Update: 27 Oct 2014

Price : $50

At a glance

  • Originator CEL-SCI Corporation; Nonindustrial source
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 22 Nov 1999 New profile
  • 22 Nov 1999 Preclinical development for Breast cancer in Germany (Parenteral)
  • 22 Nov 1999 Preclinical development for Colorectal cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top